Key result
Higher left atrial diameter (OR 1.109) and serum uric acid (OR 1.005) were independent risk factors for left atrial thrombus or spontaneous echo contrast, significantly enhancing the predictive ability of CHADS2 and CHA2DS2-VASc scores.
Why the study?
Does the addition of serum uric acid and left atrial diameter to CHADS2 and CHA2DS2-VASc scores improve the prediction of left atrial thrombus or spontaneous echo contrast in patients with nonvalvular atrial fibrillation?
Observational (n=284)
No
Does the addition of serum uric acid and left atrial diameter to CHADS2 and CHA2DS2-VASc scores improve the prediction of left atrial thrombus or spontaneous echo contrast in patients with nonvalvular atrial fibrillation?
Odds Ratio: 1.109 (95% CI 1.033–1.191)
p-value: p=0.004
Adding serum uric acid and left atrial diameter to standard risk scores may help identify a borderline high-risk group of NVAF patients to guide clinical anticoagulant therapy.
May refine thrombus risk stratification when added to CHA2DS2-VASc in NVAF; leaves open whether it should guide anticoagulation.
As for nonvalvular atrial fibrillation (NVAF) patients with left atrial thrombus or spontaneous echo contrast (LAT/SEC), we evaluated the additional predictive value of serum uric acid (SUA) and Left atrial diameter (LAD) for CHADS2 and CHA2DS2-VASc, and explored the influence from the level of SUA and LAD to LAT/SEC in moderate risk group. Thus, we put forward the concept of a borderline high risk group to guide clinical anticoagulant therapy in patients with NVAF.
No takes yet. Share an insight, caveat, or question.
Ning et al. (2017) conducted an observational in Nonvalvular atrial fibrillation (n=284). Serum uric acid and left atrial diameter vs. Lower levels of serum uric acid and left atrial diameter was evaluated on Left atrial thrombus or spontaneous echo contrast (LAT/SEC) (OR 1.109, 95% CI 1.033-1.191, p=0.004). Higher left atrial diameter (OR 1.109) and serum uric acid (OR 1.005) were independent risk factors for left atrial thrombus or spontaneous echo contrast, significantly enhancing the predictive ability of CHADS2 and CHA2DS2-VASc scores.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: